Standards for reporting prognostic tumor marker studies

Journal of Clinical Oncology

Volumn 23, Issue 36, 2005, Pages 9053-9054

  Alonzo, Todd A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CANCER RESEARCH; EDITORIAL; GENE EXPRESSION; MASS SPECTROMETRY; METHODOLOGY; NEPHROBLASTOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SCIENTIFIC LITERATURE; TREATMENT OUTCOME; HUMAN; INFORMATION PROCESSING; NEOPLASM; NOTE; STANDARD;

DATA COLLECTION; GUIDELINES; HUMANS; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33644553034     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.3778     Document Type: Editorial

References (7)

1. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072, 2005
2. Moher D, Schulz KF, Altman D, et al: The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285:1987-1991, 2001
3. Bossuyt PM, Reitsma JB, Bruns DE, et al: The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration. Clin Chem 49:1-6, 2003
4. Dome JS, Bockhold CA, Li SM, et al: High telomerase RNA expression level is an adverse prognostic factor for favorable histology Wilms' tumor. J Clin Oncol 23:9138-9145, 2005
5. Pepe MS, Etzioni R, Feng Z, et al: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:1054-1061, 2001
6. Baker SG: The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst 95:511-515, 2003
7. Pepe MS, Janes H, Longton G, et al: Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159:882-890, 2004